Realta Investment Advisors’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Realta Investment Advisors’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-539	Closed	-$7.28K	–	411
2024 Q2	$7.28K	Hold	539	–	–	﹤0.01%	695
2024 Q1	$8.96K	Buy	+539	New	+$8.3K	﹤0.01%	707
2023 Q4	–	Sell	-539	Closed	-$6.96K	–	484
2023 Q3	$6.96K	Hold	539	–	–	﹤0.01%	697
2023 Q2	$6.96K	Buy	+539	New	+$7.06K	﹤0.01%	751
2023 Q1	–	Sell	-539	Closed	-$7.4K	–	474
2022 Q4	$7.4K	Hold	539	–	–	﹤0.01%	745
2022 Q3	$8K	Buy	+539	New	+$8.7K	﹤0.01%	713
2020 Q1	–	Sell	-539	Closed	-$13K	–	494
2019 Q4	$13K	Buy	+539	New	+$11.4K	﹤0.01%	1059

Other funds holding CNCR

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBPWM

Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SWA

SOA Wealth Advisors New York $595M AUM 25.98% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Realta Investment Advisors's CNCR Position: Q3 2024 in Review

Realta Investment Advisors sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q3 2024, closing a stake of 539 shares — an estimated $7.28K sold.

Realta Investment Advisors first reported a position in CNCR in Q4 2019 and held it in 7 quarters. The position peaked at $13K in Q4 2019. 11 funds tracked by Wall St. Rank hold CNCR as of Q3 2024.

Realta Investment Advisors reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q3 2024 after selling out during the quarter.
Realta Investment Advisors sold 539 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q3 2024, an estimated $7.28K.
Realta Investment Advisors first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2019 and held it in 7 quarters.
Realta Investment Advisors's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $13K in Q4 2019.
11 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q3 2024.

Based on Realta Investment Advisors's 13F filing for Q3 2024, filed 29 Oct 2024.